The partial inhibition in tumor growth observed with JNJ-61186372-IgG2σ and the c-Met monovalent antibody was proposed to be due to inhibition of c-Met signaling as the in vitro data and in vivo H1975 model data presented here suggest that the EGFR arm drives the Fc effector mechanism. The gene discussed is EGFR; the disease is neoplasm.